<DOC>
	<DOCNO>NCT01088256</DOCNO>
	<brief_summary>The purpose study determine efficacy etoricoxib pain patient . The investigator assume patient neuropathic pain great pain relief patient placebo .</brief_summary>
	<brief_title>Efficacy Etoricoxib Peripheral Hyperalgesia</brief_title>
	<detailed_description>Animal experiment analyse anti-hyperalgesic effect Coxibs show inconsistent result due different use dosage vary different pain model . Theoretical use NSAIDs rational , particularly Coxibs part neuropathic pain management . But new topical review , valid information available effectiveness drug human neuropathic pain model patient different underlying mechanism , e.g . without hyperalgesia .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Peripheral Nerve Injuries</mesh_term>
	<mesh_term>Causalgia</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Patients 18 year Persistent moderate severe pain ( &gt; 4 NRS ( 1..10 ) ) rest ( average three daily assessment use diary least two day ) . Neuropathic pain associate clinical neurologically proven peripheral nerve injury , radiculopathy , postherpetic neuralgia polyneuropathy CRPS One two follow QST phenotype baseline assessment : sign peripheral hyperalgesia ( mean , pathological decrease heat pain threshold and/or pathological decrease muscle pain threshold ) without sign peripheral hyperalgesia ( pathological decrease heat and/or muscle pain threshold ) Patients gender Signed consent form Patients ability understand follow instruction doctor Excluded patient Parkinson 's disease history cerebral vascular insult nerve injury . Excluded also patient contradiction use Etoricoxib : Hypersensitivity active substance excipients . Active peptic ulceration active gastrointestinal ( GI ) bleeding . Patients experience bronchospasm , acute rhinitis , nasal polyp , angioneurotic oedema , urticaria , allergictype reaction take acetylsalicylic acid NSAIDs include COX2 ( cyclooxygenase2 ) inhibitor . Pregnancy lactation Severe hepatic dysfunction ( serum albumin &lt; 25 g/l ChildPugh score ≥10 ) . Estimated renal creatinine clearance &lt; 30 ml/min . Inflammatory bowel disease . Congestive heart failure ( NYHA IIIV ) . Patients hypertension whose blood pressure persistently elevate 140/90mmHg adequately control Established ischemic heart disease , peripheral arterial disease , and/or cerebrovascular disease . Intake one follow drug ( current last 3 day ) selectiveserotoninreuptakeinhibitor cetoconazole rifampicin phenytoin carbamazepine dexamethasone systemic corticoid traditional nonsteroidal antiphlogistics cyclooxygenaseinhibitors immunosuppressive TNFαinhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>CRPS</keyword>
	<keyword>Morbus Sudeck</keyword>
	<keyword>Causalgia</keyword>
	<keyword>Etoricoxib</keyword>
	<keyword>Polyneuropathy</keyword>
	<keyword>post herpetic neuralgia</keyword>
	<keyword>peripheral nerve injury</keyword>
	<keyword>radiculopathy</keyword>
	<keyword>Nervenverletzung</keyword>
	<keyword>postherpetische Neuralgie</keyword>
	<keyword>COX-2-Inhibitor</keyword>
</DOC>